English
Home > Products > CAS NO 129453-61-8

China CAS NO 129453-61-8 Factory

We rely upon strategic thinking, constant modernisation in all segments, technological advances and of course upon our employees that directly participate in our success for CAS NO 129453-61-8,129453-61-8,Fulvestrant API,Fulvestrant, Should you pursuit the Hi-quality, Hi-stable, Aggressive price tag parts, business name is your most effective choice!
CAS NO 129453-61-8, With the enterprising spirit of"" high efficiency, convenience, practicality and innovation"", and in line with such serving guidance of ""good quality but better price, "" and ""global credit"", we're striving to cooperate with the automobile parts companies all over the world to make a win-win partnership.

Related Products

Hot Products

  • N-Hydroxysuccinimide

    N-Hydroxysuccinimide

    Product Name:N-Hydroxysuccinimide
    Molecular Formula:C4H5NO3
    Molecular Weight:115.09
    CAS Registry Number:6066-82-6
  • Fondaparinux sodium

    Fondaparinux sodium

    Product Name:Fondaparinux sodium
    Molecular Formula:C31H43N3O49S8.10Na
    Molecular Weight;1728.08
    CAS Registry Number;114870-03-0
  • Flutamide

    Flutamide

    Product Name:Flutamide
    Molecular Formula:C11H11F3N2O3
    Molecular Weight;276.21
    CAS Registry Number;13311-84-7
  • Ligustrazine Phosphate

    Ligustrazine Phosphate

    Product Name:Ligustrazine Phosphate
    Molecular Formula:C8H15N2O4P
    Molecular Weight;234.19
    CAS Registry Number;848645-86-3
  • Ceftizoxime

    Ceftizoxime

    Product Name:Ceftizoxime
    Molecular Formula:C13H13N5O5S2
    Molecular Weight;383.4
    CAS Registry Number;68401-81-0
  • Diacerein

    Diacerein

    Product Name:Diacerein
    Molecular Formula:C19H12O8
    Molecular Weight;368.29
    CAS Registry Number;13739-02-1
  • Related Blog
  • Reviews

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • Bosutinib CAS 380843-75-4

    Chemical name:4-(2,4-dichloro-5-methoxyanilino)-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept